Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospekta for ADHD in Children
NCT04569357Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Nov 2020
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of Prospekta in attention deficit hyperactivity disorder (ADHD), sponsored by Materia Medica Holding. Started Nov 2020; status: completed.
02
Drugs
Prospekta
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04569357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569357.